echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Combination of Chinese and Western Medicine | "Jinguang Program" Brings New Choices for Clinical Treatment of Diabetes

    Combination of Chinese and Western Medicine | "Jinguang Program" Brings New Choices for Clinical Treatment of Diabetes

    • Last Update: 2022-05-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Diabetes is one of the major challenges to human health in the 21st century
    .
    The latest data show that the prevalence of diabetes among adults in China continues to rise, reaching 11.
    9%, but the national diabetes awareness rate, treatment rate and control rate are all low

    .
    Diabetes has brought a huge social and economic burden to our country

    .
    For this chronic metabolic disease with a long course and great harm, the exploration of how to formulate a more effective, safe and economical clinical medication plan has never stopped

    .

    diabetes

     


    Academician Tong Xiaolin and Professor Lian Fengmei of Guang'anmen Hospital of China Academy of Chinese Medical Sciences have carried out many explorations in the treatment of type 2 diabetes, and achieved many research results with clinical value

    .
    This article summarizes the clinical study of Jinlida granules combined with metformin in the treatment of type 2 diabetes shared and
    interpreted by Professor Lian Fengmei .

    Interpreting Metformin

     


    Exploring better options in hotspots, treating diabetes with integrated traditional Chinese and Western medicine


    Exploring better options in hotspots, treating diabetes with integrated traditional Chinese and Western medicine

     


    Q: The team of Academician Tong Xiaolin has carried out a clinical study on Jinlida Granules combined with metformin (hereinafter referred to as "Jinguan Program") for metformin in patients with substandard type 2 diabetes

    .
    As one of the main participants in the study, please share your thoughts on the treatment population and treatment options for this study

    .

     


    Professor Lian Fengmei: Metformin is a classic drug that is widely used in clinical treatment of type 2 diabetes.
    It has multiple therapeutic targets and is
    the first-line drug recommended by domestic and foreign diabetes treatment
    guidelines
    .
    However, in actual clinical work, there are still a large proportion of patients whose blood sugar is not controlled to an ideal level after receiving metformin treatment alone, which brings treatment difficulties to clinicians

    .
    Therefore, how to combine clinical practice, select appropriate drugs, and formulate a better combined treatment plan to benefit this type of patients has become the key to research

    .

    guide

     


    Academician Tong Xiaolin has devoted himself to the research of traditional Chinese medicine in the field of diabetes prevention and treatment for many years.
    During the research process, he gradually realized that the disorder of the spleen and stomach is the most important feature of diabetes, especially type 2 diabetes

    .
    Jinlida Granules is an innovative patented drug developed under the guidance of collateral disease theory.
    It has unique advantages for patients with spleen and stomach dysfunction and thick and greasy tongue coating, and it has sufficient theoretical basis for its combined use with metformin

    .

     


    Clinical data is the foundation, and the "Zinguanidine Program" brings more benefits to diabetic patients


    Clinical data is the foundation, and the "Zinguanidine Program" brings more benefits to diabetic patients

     


    Q: During the exploration process of this study, what advantages and characteristics did the combination of the two drugs show?

     


    Professor Lian Fengmei: The study was conducted in a randomized, double-blind, placebo, and parallel controlled manner, and was carried out in accordance with international standard intervention programs.
    All subjects were randomized to receive Jinlida granules on the basis of metformin treatment.
    Or placebo treatment, after 12 weeks of treatment, the patient's symptoms and changes in various indicators were observed

    .


    The results of the study show that Jinlida Granules combined with metformin can further reduce the glycated hemoglobin (HbA
    1c ) of patients by 0.
    92%, reduce fasting blood glucose and 2-hour postprandial blood glucose levels, improve insulin resistance, and improve insulin sensitivity and islet β-cell function index

    .
    At the same time, clinical symptoms such as dry mouth, thirst, and fatigue were significantly improved, and the
    quality of life
    of patients was significantly improved .
    It can be said that Jinlida granules combined with metformin is a very good combination drug choice for the treatment of diabetes

    .

    1c Quality of life

     


    In order to further explore the advantageous population of Jinlida granule treatment, the researchers also conducted a further stratified analysis of the gender, blood sugar level, islet function, age, course of disease, body mass index (BMI) and other factors of the patients in the study

    .
    The results confirmed that Jinlida granules combined with metformin had better curative effect for elderly patients aged >60 years with poor blood sugar control

    .
    It is believed that with the continuous optimization and in-depth research of the patient population, clinicians can use the combined regimen in a targeted manner, so that the benefited population will be wider

    .

     


    To improve islet function and metabolism, Jinlida granules exert their curative effect through multiple functions


    To improve islet function and metabolism, Jinlida granules exert their curative effect through multiple functions

     

     


    Q: In addition to the combination of metformin and metformin to treat patients who fail to meet the standard of metformin alone, what advantages and characteristics does Jinlida granule show in other diabetic patients?

     


    Prof.
    Lian Fengmei: After the study, we summarized all randomized controlled studies (RCTs) of Jinlida granules in combination with western medicine, and after excluding the studies with lower design quality, we conducted a meta-analysis of the remaining studies (15 studies).
    RCT, a total of 1810 patients)

    .


    The results of the study show that compared with only metformin, insulin, sulfonylureas, insulin sensitizers and other hypoglycemic drugs, the addition of Jinlida granules can significantly improve the patient's islet β-cell function and metabolic status, and reduce fasting blood sugar.
    , 2-hour postprandial blood glucose and HbA
    1c levels, and weight loss, with good safety
    .
    This suggests that Jinlida granules combined with other hypoglycemic western medicines can also exert their due curative effect, providing additional benefits for the type 2 diabetes patient population

    .

    1c

     


    Related Reading


    Related Reading

     


    The "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)" issued by the Diabetes Society of the Chinese Medical Association (CDS) pointed out: "For patients who take a stable dose of metformin and still do not meet the blood sugar level, Jinlida Granules can further reduce blood sugar and increase β-cell blood sugar levels.
    Functional index and insulin sensitivity, and improve thirst, fatigue, constipation and other symptoms; adding Jinlida granules on the basis of conventional hypoglycemic can further reduce HbA
    1c , improve islet function, and reduce body weight
    .
    " Recommended "Type 2 Diabetic patients can take Jinlida granules in addition to metformin and other hypoglycemic drugs

    .
    "

    1c

     


    Based on the significant curative effect of Jinlida Granules in the prevention and treatment of diabetes, it has been successively approved by the "China Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)", "International Guidelines for Diabetes Diabetes
    Diagnosis and Treatment with Traditional Chinese Medicine ", "Traditional Chinese Medicine Clinical Guidelines for Diabetic Peripheral Neuropathy" and "Traditional Chinese Medicine Guidelines for Diabetes Diabetes".
    Guidelines for Clinical Evidence-Based Practice of Medicine, Guidelines for Clinical Application of Chinese Patent Medicines - Diabetes Volume, Chinese Standards for Diagnosis and Treatment of Type 2 Diabetes (2019 English Version), Expert
    Consensus on Clinical Drugs for Diabetic Microcirculation Disorders, Clinical Differentiation and Treatment of Traditional Chinese Medicine, etc.
    Guidelines, consensus, and textbooks are listed as recommended drugs

    .
    At the same time, the "Standardized Research on the Combined Application of Traditional Chinese and Western Medicine with Jinlida Granules as a Demonstration" won the second prize of Science and Technology of the Chinese Society of Traditional Chinese Medicine in 2019

    .

    Diagnosis and Treatment Consensus

     

     



    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.